Eli Lilly & Co. (LLY)

114.07
0.88 0.78
NYSE : Health Technology
Prev Close 113.19
Open 113.02
Day Low/High 112.86 / 114.13
52 Wk Low/High 101.36 / 132.13
Volume 3.36M
Avg Volume 3.20M
Exchange NYSE
Shares Outstanding 960.13M
Market Cap 108.68B
EPS 3.10
P/E Ratio 25.15
Div & Yield 2.58 (2.24%)

Putting Amgen's Q2 Earnings Under the Microscope

Here we break down the numbers of some of the company's top drugs, but we now only have 175 shares remaining in this tag end of a position, as there are better health care stocks in the market right now.

Stocks Fall as Trump Casts Doubts on China Trade Deal, Fed Meeting Kicks Off

Stocks Fall as Trump Casts Doubts on China Trade Deal, Fed Meeting Kicks Off

Stocks decline Tuesday as investors digest a plate full of earnings reports, the start of the two-day Fed meeting, and President Trump's remarks doubting the success of U.S. trade talks with China.

Eli Lilly Tops Q2 Profit Forecast, Lifts 2019 Guidance, as Trulicity Sales Surge

Eli Lilly Tops Q2 Profit Forecast, Lifts 2019 Guidance, as Trulicity Sales Surge

Eli Lilly posted stronger-than-expected second quarter earnings Tuesday, and boosted its full-year profit forecast, thanks in part to a surge in sales of its key diabetes treatment.

Trading Apple and Netflix, Beyond Meat Earnings: Market Recon

Trading Apple and Netflix, Beyond Meat Earnings: Market Recon

Overall, expect trading volume, with notable exception of action in specific names reporting earnings, to remain on the light side right through later Wednesday afternoon.

Capital One, Apple, AMD, Beyond Meat, Federal Reserve - 5 Things You Must Know

Capital One, Apple, AMD, Beyond Meat, Federal Reserve - 5 Things You Must Know

U.S. stock futures point lower on Tuesday, the first day of a critical two-day meeting of the Federal Reserve, and ahead of quarterly earnings from tech giant Apple; the earnings calendar also includes reports from Merck, Procter & Gamble, Mastercard and AMD; Capital One says a hacker got access to the personal information of more than 100 million of its credit card customers and applicants.

Lilly Reports Second-Quarter 2019 Financial Results, Raises 2019 EPS Guidance

Lilly Reports Second-Quarter 2019 Financial Results, Raises 2019 EPS Guidance

- Revenue in the second quarter of 2019 grew 1 percent, driven by 6 percent volume growth. Key growth products launched since 2014, including Trulicity, Taltz, Jardiance, Verzenio, Olumiant, Basaglar, Emgality and Cyramza, contributed 13 percentage points of revenue growth and represented approximately 43 percent of total revenue.

Lilly's Verzenio® (abemaciclib) Significantly Extended Life In Women With HR , HER2- Advanced Breast Cancer In MONARCH 2

Lilly's Verzenio® (abemaciclib) Significantly Extended Life In Women With HR , HER2- Advanced Breast Cancer In MONARCH 2

Verzenio is the first and only CDK4 & 6 inhibitor in combination with fulvestrant to achieve statistically significant improvement in overall survival

Here's a Prescription for Eli Lilly Stock: Don't Swallow Yet

Here's a Prescription for Eli Lilly Stock: Don't Swallow Yet

With prices in a downtrend with a $95 price target, hold off on purchases until prices hold for the drugmaker.

Don't Trade, Invest: Cramer's 'Mad Money' Recap (Monday 7/15/19)

Don't Trade, Invest: Cramer's 'Mad Money' Recap (Monday 7/15/19)

Jim Cramer says don't trade earnings season, invest in it -- and invest the time needed to be a smart, successful investor.

Bristol-Myers Squibb, Eli Lily, DuPont: 'Mad Money' Lightning Round

Bristol-Myers Squibb, Eli Lily, DuPont: 'Mad Money' Lightning Round

Jim Cramer weighs in on Bristol-Myers Squibb, Eli Lily, DuPont, Marvell Technology, General Motors, Kraft Heinz, Maxar Technologies, and more.

Lilly Presents New Findings On Stigma Faced By People With Migraine Based On Interim Results From The OVERCOME Observational Study

Lilly Presents New Findings On Stigma Faced By People With Migraine Based On Interim Results From The OVERCOME Observational Study

-Data from OVERCOME shed new light on migraine stigma by examining attitudes through the eyes of people who have not been diagnosed with migraine[1]

Lilly's OVERCOME Observational Study Reveals Inconsistent And Sub-Optimal Treatment Landscape For Migraine

Lilly's OVERCOME Observational Study Reveals Inconsistent And Sub-Optimal Treatment Landscape For Migraine

-Data from OVERCOME showed that inconsistent care patterns, including high use of emergency department/urgent care settings, may be contributing to misdiagnosis, sub-optimal treatment and increased healthcare utilization(1)

AHS 2019: Post-Hoc Analyses Of Phase 3 Pivotal Studies Of Emgality® (galcanezumab-gnlm) Show Improvements In Daily Functioning And Reductions In Disability In Patients With Chronic And Episodic Migraine

AHS 2019: Post-Hoc Analyses Of Phase 3 Pivotal Studies Of Emgality® (galcanezumab-gnlm) Show Improvements In Daily Functioning And Reductions In Disability In Patients With Chronic And Episodic Migraine

-Results showed that treatment with Emgality, when compared to placebo, resulted in lower levels of migraine-related disability and fewer restrictions on daily activities that are limited by migraine, such as relationships with family and friends, leisure time, productivity, concentration, energy and fatigue(1)

Dow, S&P 500 Post Record Closes on Rate Cut Hopes, Healthcare Rally

Dow, S&P 500 Post Record Closes on Rate Cut Hopes, Healthcare Rally

The Dow & S&P 500 closed at record highs with the S&P barely missing ending the day above 3,000.

AstraZeneca Biopharma President Talks Drug Rebates, Pricing

AstraZeneca Biopharma President Talks Drug Rebates, Pricing

Is pharma feeling the pressure now that PBM stocks are released from regulatory risk?

Lilly Announces Changes In Senior Leadership

Lilly Announces Changes In Senior Leadership

Mike Harrington, senior vice president and general counsel, to retire at year end

New England Journal Of Medicine Publishes Positive Phase 3 Data For Emgality® (galcanezumab-gnlm) In Episodic Cluster Headache

New England Journal Of Medicine Publishes Positive Phase 3 Data For Emgality® (galcanezumab-gnlm) In Episodic Cluster Headache

INDIANAPOLIS, July 11, 2019 /PRNewswire/ --  Eli Lilly and Company (NYSE: LLY) announced today that the New England Journal of Medicine published positive Phase 3 study results of Emgality ® (galcanezumab-gnlm) for the treatment of episodic cluster...

Lilly Announces Upcoming Presentation Of New Data Indicating Rise In Opioid Use For Migraine Treatment

Lilly Announces Upcoming Presentation Of New Data Indicating Rise In Opioid Use For Migraine Treatment

-Findings showed that nearly 1 in 5 people with migraine (19%) are currently using opioids to treat their disease, up from 16 percent in 2009(1,2)

Lilly Confirms Date And Conference Call For Second-Quarter 2019 Financial Results Announcement

Lilly Confirms Date And Conference Call For Second-Quarter 2019 Financial Results Announcement

INDIANAPOLIS, July 9, 2019 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will announce its second-quarter 2019 financial results on Tuesday, July 30, 2019.

Stocks End Lower; Jobs Rebound Trims Hope of Fed Rate Cut

Stocks End Lower; Jobs Rebound Trims Hope of Fed Rate Cut

Stocks fell Friday as a surprising rebound in June hiring reduced the likelihood of an interest rate cut by the Federal Reserve.

My 3 Predictions for the Second Half of 2019

My 3 Predictions for the Second Half of 2019

Watch the Russell 2000, housing activity, and mergers and acquisitions.

Lilly's AWARD-11 Trial Studying Higher Investigational Doses Of Trulicity® (dulaglutide) Demonstrated Superiority In A1C Reduction In People With Type 2 Diabetes

Lilly's AWARD-11 Trial Studying Higher Investigational Doses Of Trulicity® (dulaglutide) Demonstrated Superiority In A1C Reduction In People With Type 2 Diabetes

INDIANAPOLIS, June 26, 2019 /PRNewswire/ -- Eli Lilly and Company's (NYSE: LLY) trial studying higher investigational doses of Trulicity ® (dulaglutide) met its primary efficacy endpoint of superiority, significantly reducing A1C from baseline in people...

U.S. FDA Grants Fast Track Designation To Empagliflozin For The Treatment Of Chronic Heart Failure

U.S. FDA Grants Fast Track Designation To Empagliflozin For The Treatment Of Chronic Heart Failure

- Fast Track designation facilitates development of new therapies that treat serious conditions and fulfill an unmet medical need

AbbVie Joins Giant Acquisition Trend in Big Pharma With Allergan Deal

AbbVie Joins Giant Acquisition Trend in Big Pharma With Allergan Deal

The proposed, $63 billion transaction is the latest deal in an industry where it can be cheaper to buy the science of another company than develop products.

A Handful of Small Biotechs That Make for Merger Chatter

A Handful of Small Biotechs That Make for Merger Chatter

The names include a veterinary drug concern plus companies with successful drugs on the market.

Lilly Declares Third-Quarter 2019 Dividend

Lilly Declares Third-Quarter 2019 Dividend

INDIANAPOLIS, June 19, 2019 /PRNewswire/ -- The board of directors of Eli Lilly and Company (NYSE: LLY) has declared a dividend for the third quarter of 2019 of $0.

Pfizer Nabs Array Biopharma in $11.4 Billion Takeover of Cancer Drug Specialist

Pfizer Nabs Array Biopharma in $11.4 Billion Takeover of Cancer Drug Specialist

Pfizer said Monday it has agreed to acquire Array Biopharma in an all-cash deal that values the cancer drug specialist at around $11.4 billion.

IPO Gives Chinese Couple a 'Hansoh' Sum

IPO Gives Chinese Couple a 'Hansoh' Sum

The initial public offering of Hansoh Pharmaceutical Group made the Chinese couple Zhong Huijuan and Sun Piaoyang the richest in the nation.

Lilly Presents Positive Results For Taltz® (ixekizumab) Vs. Humira® (adalimumab) In A Head-to-Head (SPIRIT-H2H) Superiority Study In Patients With Active Psoriatic Arthritis At The European Congress Of Rheumatology

Lilly Presents Positive Results For Taltz® (ixekizumab) Vs. Humira® (adalimumab) In A Head-to-Head (SPIRIT-H2H) Superiority Study In Patients With Active Psoriatic Arthritis At The European Congress Of Rheumatology

INDIANAPOLIS, June 14, 2019 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today that the company will present positive findings from the Phase 3b/4 SPIRIT-Head-to-Head (H2H) study in patients with active psoriatic arthritis (PsA) as a...

TheStreet Quant Rating: B- (Buy)